MiniMed initiated with an Overweight at Barclays

Barclays initiated coverage of MiniMed (MMED) with an Overweight rating and $26 price target The company has a “strong cadence” of new product launches in the U.S. and globally which should drive accelerating growth over the upcoming quarters and well into 2027 and 2028, the analyst tells investors in a research note. Barclays finds the shares attractively valued at current levels.